Successful use of azithromycin for Escherichia coli-associated renal allograft malakoplakia: a report of two cases.
Allografts
/ microbiology
Anti-Bacterial Agents
/ administration & dosage
Azithromycin
/ administration & dosage
Escherichia coli
/ drug effects
Escherichia coli Infections
/ drug therapy
Female
Humans
Kidney Transplantation
/ adverse effects
Malacoplakia
/ drug therapy
Microbial Sensitivity Tests
Middle Aged
Postoperative Complications
/ drug therapy
Enterobacterales
Enterobacteriaceae
Gram-negative
Macrolide
Treatment
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
31
12
2020
accepted:
03
05
2021
pubmed:
16
5
2021
medline:
22
12
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
Malakoplakia is a chronic granulomatous disease associated with incomplete clearance of bacterial pathogens. A multimodal approach to therapy includes antimicrobials with intracellular activity, reduction in immunosuppression, and debulking of lesions. Azithromycin has an intracellular mechanism of action and enhanced Gram-negative activity compared to other macrolides. Despite some in vitro data to support its use, there are no clinical breakpoints or epidemiological cut-off values for most Enterobacterales from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory Standards Institute (CLSI). We present two cases, previously unreported, of Escherichia coli associated renal allograft malakoplakia successfully treated with azithromycin.
Identifiants
pubmed: 33990891
doi: 10.1007/s10096-021-04270-x
pii: 10.1007/s10096-021-04270-x
doi:
Substances chimiques
Anti-Bacterial Agents
0
Azithromycin
83905-01-5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2627-2631Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bertrand D, Chavarot N, Gatault P, Garrouste C, Bouvier N, Grall-Jezequel A, Jaureguy M, Caillard S, Lemoine M, Colosio C, Golbin L, Rerolle J-P, Thierry A, Sayegh J, Etienne I, Lebourg L, Sberro R, Guerrot D (2020) Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrol Dial Transplant 35(2):336–345. https://doi.org/10.1093/ndt/gfz255
doi: 10.1093/ndt/gfz255
pubmed: 32030416
Blair JEJ, MacLennan GT (2005) Malakoplakia. J Urol 173(3):986–986. https://doi.org/10.1097/01.ju.0000153740.91749.ac
doi: 10.1097/01.ju.0000153740.91749.ac
pubmed: 15711361
Evans NL, French J, Rose MB (1998) Renal malacoplakia: an important consideration in the differential diagnosis of renal masses in the presence of Escherichia coli infection. Br J Radiol 71(850):1083–1085. https://doi.org/10.1259/bjr.71.850.10211070
doi: 10.1259/bjr.71.850.10211070
pubmed: 10211070
Fitzgibbons PL (2018) Histochemistry in the diagnosis of non-neoplastic gastrointestinal disorders. Semin Diagn Pathol 35(6):370–380. https://doi.org/10.1053/j.semdp.2018.10.002
doi: 10.1053/j.semdp.2018.10.002
pubmed: 30366790
Goel D, Pradhan D, Tiwary A (2018) Fluorodeoxyglucose avid malakoplakia of the laryngohypopharynx masquerading as malignant tumor: a pathological enigma and clinical dilemma. Indian J Pathol Microbiol 61(2):298. https://doi.org/10.4103/IJPM.IJPM_156_17
doi: 10.4103/IJPM.IJPM_156_17
pubmed: 29676386
Gomes C, Ruiz-Roldán L, Mateu J, Ochoa TJ, Ruiz J (2019) Azithromycin resistance levels and mechanisms in Escherichia coli. Sci Rep 9. https://doi.org/10.1038/s41598-019-42423-3
Köksal D, Ozcan A, Demirağ F, Akman B, Acar LN, Gülhan E, Özmen Ö (2014) Pulmonary malakoplakia: a case report and review of the literature. Tuberk Toraks 62(3):248–252
doi: 10.5578/tt.7840
Lococo F, Montanari G, Mengoli MC, Ferrari F, Spagnolo P, Rossi G (2015) Hemoptysis and progressive dyspnea in a 67-year-old woman with history of renal transplantation. Am J Respir Crit Care Med 193(6):e12–e13. https://doi.org/10.1164/rccm.201511-2134IM
doi: 10.1164/rccm.201511-2134IM
Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M (2013) Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother 57(4):1736–1742. https://doi.org/10.1128/AAC.02011-12
doi: 10.1128/AAC.02011-12
pubmed: 23357769
pmcid: 3623349
Mookerji N, Skinner T, McAlpine K, Warren J (2019) Case – Malakoplakia in a 58-year-old male following living donor renal transplantation. Can Urol Assoc J 13(1):E19–E21. https://doi.org/10.5489/cuaj.5282
doi: 10.5489/cuaj.5282
Nieto-Ríos JF, Ramírez I, Zuluaga-Quintero M, Serna-Higuita LM, Gaviria-Gil F, Velez-Hoyos A (2017) Malakoplakia after kidney transplantation: Case report and literature review. Transpl Infect Dis 19(5):e12731. https://doi.org/10.1111/tid.12731
doi: 10.1111/tid.12731
Parnham MJ, Erakovic Haber V, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R (2014) Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 143(2):225–245. https://doi.org/10.1016/j.pharmthera.2014.03.003
doi: 10.1016/j.pharmthera.2014.03.003
pubmed: 24631273
Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA (2011) Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121(9):3554–3563. https://doi.org/10.1172/JCI46095
doi: 10.1172/JCI46095
pubmed: 21804191
pmcid: 3163956
Tulpule MS, Bharatia PR, Pradhan AM, Tawade YV (2017) Cutaneous malakoplakia: interesting case report and review of literature. Indian Journal of Dermatology, Venereology, and Leprology 83(5):584. https://doi.org/10.4103/ijdvl.IJDVL_145_17
Yousef GM, Naghibi B (2007) Malakoplakia outside the urinary tract. Arch Pathol Lab Med 131(2):297–300. https://doi.org/10.1043/1543-2165(2007)131[297:MOTUT]2.0.CO;2
doi: 10.1043/1543-2165(2007)131[297:MOTUT]2.0.CO;2
pubmed: 17284117
Zimmermann P, Ziesenitz VC, Curtis N, Ritz N (2018) The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.00302